November 11, 2025 — Leads & Copy —
November 11, 2025 — Leads & Copy —TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”) announced that CEO and President Mary Szela and CFO David Patience will participate in two investor conferences in November and December.
The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum will feature management in one-on-one meetings and a corporate overview on Thursday, November 20, at 2:30 p.m. ET. A live webcast link is available.
The 37th Annual Piper Healthcare Conference in New York, NY, will include management participating in one-on-one meetings and a corporate overview on Tuesday, December 2, at 3:10 p.m. ET. A live webcast link is available.
A webcast replay of the corporate overview will be available for 90 days following the presentation in the Events section of the TriSalus Investor website.
TriSalus Life Sciences® is focused on oncology and seeks to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 agonist, for various therapeutic and technology applications.
TriSalus has two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, potentially improving patient outcomes.
Nelitolimod, TriSalus’ investigational immunotherapeutic candidate, is designed to treat the immunosuppressive environment created by tumors, which can make current immunotherapies ineffective in the liver and pancreas. The company is in the final stages of data completion for several phase 1 clinical trials and will begin exploring partnership opportunities for development.
TriSalus is committed to advancing innovation that improves patient outcomes by partnering with leading cancer centers and leveraging its immuno-oncology expertise and technology development.
Mary Szela, Chief Executive Officer and President
David Patience, Chief Financial Officer
Source: TriSalus Life Sciences
